Patent · US Active

Crystalline Forms on N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]-quinolin-4-yl}oxy)phenyl]-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide

US8673912B2 · kind B2 · utility

33Cited by

0References

10Claims

0Family size

Assignee

Exelixis, Inc. · US

Inventors

Hilary Cannon · Hertford, GB
David H. Igo · Morrisville, US
Tri Minh Tran · Sacramento, US

Key dates

Filing date	Jul 16, 2010
Grant date	Mar 18, 2014
Priority date	—
Expiry date	Aug 31, 2030

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P35/02
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

This invention relates to three crystalline forms of N-[3-fluoro-4-((6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl|oxy)phenyl]-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide. Compound (I), designated as Form A, Form B, and Form C. The invention provides methods for treatment of cancer by exploiting the modulation of protein kinase activity. The invention also provides pharmaceutical compositions containing a crystalline form of Compound (I) and a pharmaceutically acceptable excipient.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.